Tesamorelin

What is Tesamorelin?

Tesamorelin is a synthetic analog of growth hormone releasing hormone (GHRH) — the hypothalamic peptide that signals the pituitary gland to produce and release growth hormone (GH). Unlike direct GH administration, Tesamorelin works through the body's own regulatory feedback mechanisms, producing a more physiological GH release pattern with a lower risk of supraphysiological levels.

Tesamorelin has FDA approval for HIV-associated lipodystrophy and is one of the most clinically studied GHRH analogs available. Its primary documented effect is a significant reduction in visceral adipose tissue (VAT) — the metabolically active fat stored around the abdominal organs that is strongly associated with cardiovascular disease, insulin resistance, and metabolic syndrome.

Beyond visceral fat reduction, Tesamorelin has demonstrated improvements in body composition (lean mass preservation), cognitive function, lipid profiles, and quality of life in clinical trials. At HydraSpa, it is prescribed as part of our body composition and longevity programs for individuals seeking evidence-based metabolic optimization.

How Tesamorelin optimizes body composition

Pituitary GH Stimulation

Tesamorelin binds to GHRH receptors on the pituitary gland, stimulating the pulsatile release of growth hormone — mimicking the body's natural GH secretion pattern rather than introducing exogenous GH.

Visceral Fat Reduction

Elevated GH levels increase lipolysis (fat breakdown) in visceral adipose tissue — the metabolically harmful fat stored around abdominal organs. Clinical trials show 15–20% reductions in VAT with consistent Tesamorelin use.

IGF-1 Upregulation

GH stimulates the liver to produce IGF-1 (insulin-like growth factor 1), which mediates many of GH's anabolic effects — supporting muscle preservation, tissue repair, and metabolic function.

Cognitive Support

Clinical studies have shown Tesamorelin improves executive function, memory, and processing speed in older adults — effects attributed to IGF-1's neuroprotective and neurogenic properties.

Lipid Profile Improvement

Tesamorelin has demonstrated improvements in triglyceride levels and HDL cholesterol in clinical trials — contributing to improved cardiovascular risk profiles alongside body composition changes.

What patients report

—

Significant reduction in visceral (abdominal) fat

—

Improved lean muscle mass preservation

—

Enhanced metabolic rate and fat oxidation

—

Improved lipid profile (triglycerides, HDL)

—

Cognitive function support — memory, focus, processing speed

—

Improved energy and physical performance

—

Better sleep quality and recovery

—

Support for insulin sensitivity and metabolic health

—

Physiological GH release — lower risk than direct GH administration

Who may benefit from Tesamorelin?

—

Adults with excess visceral adiposity seeking evidence-based reduction

—

Individuals with declining GH/IGF-1 levels associated with aging

—

Those seeking body composition improvement alongside exercise and nutrition

—

Patients in our Advanced Peptide or Longevity & Performance programs

—

Individuals with metabolic syndrome or elevated cardiovascular risk factors

—

Those seeking cognitive performance support alongside body composition goals

—

Adults who have not responded adequately to lifestyle interventions alone

Frequently asked questions

Is Tesamorelin the same as growth hormone?

No. Tesamorelin is a GHRH analog — it stimulates your pituitary gland to produce its own growth hormone rather than introducing exogenous GH. This produces a more physiological release pattern, maintains the body's natural feedback regulation, and carries a lower risk of supraphysiological GH levels.

How much visceral fat reduction can I expect?

Clinical trials have demonstrated average visceral fat reductions of 15–20% over 6–12 months of consistent Tesamorelin use. Individual results vary based on baseline body composition, diet, exercise, and adherence to the protocol.

Will Tesamorelin affect my blood sugar?

Growth hormone can transiently increase blood glucose levels. Fasting glucose and HbA1c are monitored at baseline and during treatment. Tesamorelin is generally well-tolerated in non-diabetic individuals, but your clinician will assess your metabolic health before prescribing and monitor closely during treatment.

Can I combine Tesamorelin with Sermorelin or Ipamorelin/CJC-1295?

Tesamorelin, Sermorelin, and Ipamorelin/CJC-1295 all stimulate GH release through related but distinct mechanisms. Combining them requires careful clinical judgment to avoid excessive GH stimulation. Your clinician will design a protocol that achieves your goals without creating contraindicated combinations.

How long before I see results?

Most patients notice improvements in energy and sleep quality within 4–6 weeks. Measurable changes in body composition typically become apparent at 8–12 weeks, with the most significant visceral fat reduction occurring between 3–6 months of consistent use.

Our services